Speedway Scene
Markets S&P 500 7,500.58 ▲ 0.00% Nasdaq 26,517.93 ▲ 0.00% Dow Jones 44,200.00 ▲ 0.00% US 10 Yr 4.45 ▲ 0.00% Crude Oil 76.54 ▲ 0.00% Gold 2,350.00 ▲ 0.00% Bitcoin 64,000 ▲ 0.00% FTSE 100 8,400.00 ▲ 0.00% EUR/USD 1.0850 ▲ 0.00% Nikkei 225 39,000.00 ▲ 0.00%
Topic archive

atacicept

Reporting, analysis and commentary on atacicept from Speedway Scene, drawn together from across our coverage.

1 article Latest update: 4 Jul 2026 1 section
Related sections Health
Related topics IgA nephropathy atacicept FDA decision Vera Therapeutics kidney disease nephrology Berger's disease FDA approval
Tag lead
Close-up of a laboratory scientist preparing a biologic injectable therapy for kidney disease research
Health

IgA nephropathy atacicept FDA decision looms as Vera awaits a July 7 verdict

Vera Therapeutics faces a July 7, 2026 FDA deadline on atacicept, a twice-monthly injection that could become the first dual BAFF and APRIL biologic approved for IgA nephropathy, a leading cause of kidney failure in young adults.

4 Jul 2026 ·8 min read
Keep reading

More paths through this story

This archive gathers Speedway Scene coverage of atacicept, bringing together the reporting, analysis and commentary connected to the subject.

Related topics

IgA nephropathy atacicept FDA decision Vera Therapeutics kidney disease nephrology Berger's disease FDA approval Federal Reserve Donald Trump AI infrastructure semiconductors

Related sections

Health

Latest nearby

Health · 4 Jul 2026 Aetna, Cigna Headline ACA Marketplace Insurers Exit 2026 Health · 4 Jul 2026 Dead Skua Marks First H5N1 Bird Flu Australia Detection Health · 4 Jul 2026 European heatwave 20000 deaths study exposes a toll ten times official counts Health · 4 Jul 2026 Gedatolisib Breast Cancer FDA Verdict Nears for Patients Out of Options